Zobrazeno 1 - 10
of 282
pro vyhledávání: '"Zhihong Chi"'
Autor:
Michael Lee, Jing Chen, Li Yao, Yu Chen, Yu Jiang, Feng Li, Xiubao Ren, Jun Guo, Bixia Tang, Chuanliang Cui, Gang Huang, Shuai Zhao, Zhihong Chi, Meng Qi, Xiaolu Tao, Quanli Gao, Xiaoshi Zhang, Meiyu Fang, Fei Zheng, Rongqing Li, Meijuan Gao, Ruixuan Luo, Rong Duan
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 10 (2024)
Background HBM4003 is a novel anti-CTLA-4 heavy chain-only antibody, designed to enhance Treg ablation and antibody-dependent cell-mediated cytotoxicity while ensuring a manageable safety profile. This phase I trial investigated the safety, pharmacok
Externí odkaz:
https://doaj.org/article/999bac7efb2d43c483ff80494758b040
Autor:
Huizi Lei, Yun Ling, Pei Yuan, Xieqiao Yan, Lin Wang, Yanxia Shi, Xin Yao, Hong Luo, Benkang Shi, Jiyan Liu, Zhisong He, Guohua Yu, Weiqing Han, Changlu Hu, Zhihong Chi, Chuanliang Cui, Lu Si, Jianmin Fang, Jun Guo, Xinan Sheng, Aiping Zhou, Jianming Ying
Publikováno v:
Journal of the National Cancer Center, Vol 3, Iss 2, Pp 121-128 (2023)
Background: Human epidermal growth factor receptor 2 (HER2) overexpression is related to anti-HER2 therapy in many tumors. RC48- antibody-drug conjugate (ADC) has shown promising efficacy in patients with HER2-positive locally advanced or metastatic
Externí odkaz:
https://doaj.org/article/3664bb59f9ac49d0bbc2e512ed46bf3c
Autor:
Yu Du, Zhonghui Qi, Xianbin Liang, Jie Dai, Xiaoting Wei, Xue Bai, Lili Mao, Zhihong Chi, Chuanliang Cui, Bin Lian, Bixia Tang, Xuan Wang, Yu Chen, Jun Guo, Lu Si
Publikováno v:
Dermatology Practical & Conceptual, Vol 14, Iss 1 (2024)
Introduction: Pembrolizumab is well-tolerated in pediatric patients with advanced tumors, consistent with results in adults. However, information on the safety and efficacy of adjuvant pembrolizumab in children and adolescents with melanoma is lackin
Externí odkaz:
https://doaj.org/article/f064e315e5ac491cb62b80b7418a8403
Autor:
Chuanliang Cui, Yu Chen, Zhiguo Luo, Zhengyun Zou, Yu Jiang, Hongming Pan, Qingxia Fan, Jianfu Zhao, Qing Xu, Renbing Jiang, Xuan Wang, Taiyang Ma, Zhen Guo, Lu Si, Zhihong Chi, Xinan Sheng, Yiwei Dou, Qian Tan, Di Wu, Jun Guo
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-11 (2023)
Abstract Background Pucotenlimab is a novel recombinant humanized anti-PD-1 (Programmed death-1) monoclonal antibody, which belongs to the human IgG4/kappa subtype, and can selectively block the binding of PD-1 with its ligands PD-L1 and PD-L2. Metho
Externí odkaz:
https://doaj.org/article/83c21142fb064ae8ae697bb5f09ec8bc
Autor:
Li Zhou, Xiaowen Wu, Zhihong Chi, Lu Si, Xinan Sheng, Yan Kong, Lili Mao, Bin Lian, Bixia Tang, Xieqiao Yan, Xuan Wang, Xue Bai, Siming Li, Xiaoting Wei, Juan Li, Qing Yang, Jun Guo, Chuanliang Cui
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-10 (2022)
Abstract Background Anti-programmed cell death receptor-1 (PD-1) monotherapy is the standard treatment for metastatic melanoma in current. Camrelizumab is a humanized IgG4 anti-PD-1 monoclonal antibody whose safety and efficacy have not been reported
Externí odkaz:
https://doaj.org/article/f21c870021a84320a8dfb351e754c7dc
Autor:
Xuan Wang, Jie Dai, Li Zhou, Xuefeng Xia, Xue Bai, Lu Si, Bixia Tang, Chuanliang Cui, Xiaoting Wei, Xinan Sheng, Siming Li, Zhihong Chi, Lili Mao, Bin Lian, Xieqiao Yan, Yan Kong, Caili Li, Xuan Gao, Lirui Tang, Linzi Sun, Zhonghui Qi, Zelong Xu
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 1 (2023)
Background Accumulating data suggest that mucosal melanoma, well known for its poor response to immune checkpoint blockade (ICB) and abysmal prognosis, is a heterogeneous subtype of melanoma with distinct genomic and clinical characteristics between
Externí odkaz:
https://doaj.org/article/ef571d10c780498bb9695650403c1b6b
Autor:
Lirui Tang, Xiaoting Wei, Caili Li, Jie Dai, Xue Bai, Lili Mao, Zhihong Chi, Chuanliang Cui, Bin Lian, Bixia Tang, Yu Du, Xuan Wang, Yumei Lai, Xinan Sheng, Xieqiao Yan, Siming Li, Li Zhou, Yan Kong, Zhongwu Li, Lu Si, Jun Guo
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
BackgroundAdjuvant chemotherapy has been shown to produce a favorable prognosis for patients with resectable mucosal melanoma (MM), resulting in the need for stratification to optimally select patients to benefit from adjuvant therapy. This study ana
Externí odkaz:
https://doaj.org/article/187f0f8e12054cb286a6ce844396668b
Autor:
Chuanliang Cui, Canqiang Xu, Wenxian Yang, Zhihong Chi, Xinan Sheng, Lu Si, Yihong Xie, Jinyu Yu, Shun Wang, Rongshan Yu, Jun Guo, Yan Kong
Publikováno v:
npj Genomic Medicine, Vol 6, Iss 1, Pp 1-12 (2021)
Abstract Immune checkpoint inhibitor (ICI) treatments produce clinical benefit in many patients. However, better pretreatment predictive biomarkers for ICI are still needed to help match individual patients to the treatment most likely to be of benef
Externí odkaz:
https://doaj.org/article/e97b11a5b0b44e6cb64f859733a26b77
Autor:
Xuan Wang, Jie Dai, Li Zhou, Robert Andtbacka, Jun Guo, Xue Bai, Lu Si, Bixia Tang, Chuanliang Cui, Qing Ji, Xinan Sheng, Siming Li, Zhihong Chi, Lili Mao, Bin Lian, Xieqiao Yan, Yan Kong, Jiayi Yu
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 4 (2022)
Externí odkaz:
https://doaj.org/article/916085ef2cc5452085060f7078c3188e
Autor:
Xuan Wang, Sheng Yao, Jie Dai, Li Zhou, Hui Feng, Jun Guo, Xue Bai, Lu Si, Bixia Tang, Chuanliang Cui, Xinan Sheng, Siming Li, Zhihong Chi, Lili Mao, Bin Lian, Xieqiao Yan, Yan Kong, Xiaowen Wu, Xiongwen Tang, Keith T Flaherty
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 2 (2022)
Externí odkaz:
https://doaj.org/article/bd197a1433e243a281925e32949f27b8